The Fed came very close to promising a rate cut Wednesday, and now markets are focused on a possible July rate cut.Market Insiderread more
The Fed left interest rates unchanged at its monetary policy meeting. The U.S. central bank did, however, drop the word "patient " from its statement and said it would "act as...Asia Marketsread more
Markets had expected the central bank to keep its benchmark interest rate steady while setting up a cut at the July meeting.The Fedread more
The yield on the benchmark 10-year Treasury note fell below 2% for the first time since November 2016 on Wednesday — breaching a key psychological level.Bondsread more
As the presidents of U.S. and China near a highly anticipated meeting on trade, the gap in both sides' expectations regarding a deal remains wide.World Politicsread more
Powell said policymakers are concerned about some of the recent economic developments and see a growing case for easier policy.The Fedread more
Meatless alternatives are on the rise, fueled by startups and companies. CNBC's Uptin Saiidi tried out 21 days as a vegetarian and explores whether this is a fad or the future...Food & Beverageread more
Amazon and Blue Origin founder Jeff Bezos gave more insight into his space company's lunar plans on Wednesday.Technologyread more
Sundar Pichai's note reads like a response to growing scrutiny from regulators, press and employees, and echoes a consistent theme of how Google helps people.Technologyread more
Delta warned travelers that a technical problem could delay flights on Wednesday.Airlinesread more
The Fed chief said that despite reports that Trump was looking to demote or fire him, he doesn't plan on leaving anytime soon.The Fedread more
Mylan CEO Heather Bresch shared her views on the pharmaceutical industry in an interview Friday on CNBC's "Power Lunch. "
The company manufactures EpiPen, a lifesaving medication and delivery system for people with severe allergies. Mylan was scrutinized in 2016 for its drug pricing strategy over the last decade.
On EpiPen pricing controversy: "We fixed EpiPen. We introduced a generic, $300. We cut the price in half," she said. "We took action with EpiPen. It's half the price. We're making sure everyone that needs one has one. But, importantly, it showed that the system is broken."
On President Donald Trump: "I am optimistic with this administration. … I think this administration is solution oriented," Bresch said. Health care "is a huge problem, as he said it's complicated, so it's going to have to take bold action to be able to really look at this holistically."
Prior to becoming CEO, Bresch worked as Mylan's president and chief operating officer. She served at the company for 25 years in a variety of other roles.
She also discusses:
To watch the broadcast interview in its entirety, you must be a CNBC PRO subscriber.